Allergic dermatitis due to oral ebrotidine.
We report the case of a woman who developed generalized dermatitis after 1 week of treatment with ebrotidine, a new H2-receptor antagonist taken to prevent gastroduodenal lesions caused by nonsteroidal inflammatory drugs. Patch tests with ebrotidine and other H2-receptor antagonists ranitidine, cimetidine and famotidine were negative. Oral challenge test with ebrotidine showed the development of lesions similar to those appearing previously. Oral challenge test with ranitidine and cimetidine were negative, possibly due to the difference in the side chain chemical structure of ebrotidine and other H2-receptor antagonists. This is the first reported case of allergic dermatitis caused by ebrotidine.
Carretero Aníbarro
P
P
Allergology Section, General Yagüe Hospital, Burgos, Spain.
Blanco Carmona
J
J
García González
F
F
Garcés Sotillos
M
M
Herrero Gil
D
D
Pérez Giménez
R
R
Juste Picón
S
S
D000284:Administration, Oral; D000897:Anti-Ulcer Agents / Q000009:adverse effects; D001557:Benzenesulfonates / Q000008:administration & dosage / Q000009:adverse effects*; D003872:Dermatitis / Q000209:etiology*; D003875:Drug Eruptions / Q000209:etiology*; D004342:Drug Hypersensitivity / Q000209:etiology*; D005260:Female; D006635:Histamine H2 Antagonists / Q000009:adverse effects; D006801:Humans; D008875:Middle Aged; D013844:Thiazoles / Q000008:administration & dosage / Q000009:adverse effects*
D000897:Anti-Ulcer Agents; D001557:Benzenesulfonates; D006635:Histamine H2 Antagonists; D013844:Thiazoles; C075156:ebrotidine